Evidence map›Paper›PMID 42347834›Full record

ReviewChemical Society reviews2026

Antibacterial drug discovery: challenges and preclinical promises from synthetic small molecules.

Guilherme F S Fernandes, Seong-Heun Kim, Jean L Dos Santos, Yuhang Wang, Christelle Soudy, Joanna Redmond, Daniele Castagnolo, Matthew Todd

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chemical Society reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Guilherme F S FernandesChemical Biology Science Technology Platform, The Francis Crick Institute, London NW1 1AT, UK. guilherme.fernandes@crick.ac.uk.ORCID http://orcid.org/0000-0002-7644-5466
Seong-Heun KimInstitute of Pharmaceutical Science, King's College London, London SE1 9NH, UK. seong_heun.2.kim@kcl.ac.uk.ORCID http://orcid.org/0000-0002-9774-9311
Jean L Dos SantosSchool of Pharmaceutical Sciences, São Paulo State University, Araraquara 14800903, Brazil. jean.santos@unesp.br.ORCID http://orcid.org/0000-0002-2460-2829
Yuhang WangSchool of Pharmacy, University College London, London WC1N 1AX, UK. matthew.todd@ucl.ac.uk.ORCID http://orcid.org/0000-0002-5185-1556
Christelle SoudyChemical Biology Science Technology Platform, The Francis Crick Institute, London NW1 1AT, UK. guilherme.fernandes@crick.ac.uk.ORCID http://orcid.org/0000-0003-2603-309X
Joanna RedmondChemical Biology Science Technology Platform, The Francis Crick Institute, London NW1 1AT, UK. guilherme.fernandes@crick.ac.uk.ORCID http://orcid.org/0000-0002-3200-4087
Daniele CastagnoloDepartment of Chemistry, University College London, London E20 2AE, UK. d.castagnolo@ucl.ac.uk.ORCID http://orcid.org/0000-0002-7517-5732
Matthew ToddSchool of Pharmacy, University College London, London WC1N 1AX, UK. matthew.todd@ucl.ac.uk.ORCID http://orcid.org/0000-0001-7096-4751

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past few decades, antibacterial discovery has changed substantially, yet innovation has remained slow despite the growing need for new agents active against multidrug-resistant pathogens. Progress is constrained by scientific hurdles, including target selection, penetration and efflux in bacteria, and the difficulty of translating

Indexed as

Anti-Bacterial AgentsBacteriaDrug DiscoverySmall Molecule LibrariesAnimalsHumansAnti-Bacterial AgentsSmall Molecule Libraries

Identifiers

PMID42347834
PMCPMC7619609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.